Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients
Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon
Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon
View: Text | PDF
Clinical Research and Public Health Immunology Oncology

Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients

  • Text
  • PDF
Abstract

BACKGROUND TGF-β drives fibroblast activation in cancer and is a resistance biomarker to PD-1/PD-L1 blockade.METHODS Focusing on the tumor stroma, we characterized the impact of neoadjuvant treatment with bintrafusp alfa (BA), a dual PD-L1 and TGF-β inhibitor, in a window-of-opportunity study with 6 patients with head and neck squamous cell carcinoma (HNSCC). Tumor biopsies before treatment and 3 weeks after therapy were analyzed using scRNA-seq, imaging, and spatial transcriptomics.RESULTS After treatment, we observed significantly decreased levels of activated LRRC15+ cancer-associated fibroblasts (CAFs), remodeled stromal architecture with reduced collagen I and XII content, and increased CD8+ T cell infiltration in immune-excluded tumors. These changes were independently confirmed in an additional neoadjuvant BA-treated cohort of 6 patients with HNSCC. The drastic CAF and stromal compartment reduction observed indicated a fibroblast depletion rather than a fibroblast polarization shift.CONCLUSION While our final clinical cohort does not allow assessment of the treatment effect, this study demonstrated that targeting TGF-β in patients can disrupt the tumor stroma within a short time frame. Further trials and novel biomarkers are now needed to select patients who could benefit.TRIAL REGISTRATION ClinicalTrials.gov NCT04428047.FUNDING Merck KGaA, ARC Emerging Leaders in Oncology, ANR-10-IDEX-0001-02 PSL, Centre d’Investigation Clinique IGR-Curie 1428, Site de Recherche Intégrée sur le Cancer (INCa-DGOS-Inserm-ITMO cancer_18000), French Government “Investissements d’Avenir” program, France 2030 program, Fondation pour la Recherche Médicale, Marie Skłodowska-Curie grant agreement 847718, Cooperative Research and Development Agreement with EMD Serono, and NIH (ZIA BC 010666).

Authors

Caroline Hoffmann, Jan-Timon Werle, Philémon Sirven, Mamy Andrianteranagna, Jocelyn Gal, Wiem Lassoued, Jerzy Klijanienko, Jeremy Mesple, Benjamin Demaille, Abdenour Abbas, Valentine Gauthier, Kyra J.E. Borgman, Isabelle Puisieux, Serena Janho dit Hreich, Olivier Choussy, Gregoire Marret, Sonia Lameiras, Nathalie Badois, Antoine Dubray-Vautrin, Gilles Dolivet, Lionnel Geoffrois, Renaud Leclère, Wail Zeitouni, Noemie Robil, Jane Merlevede, Altynbek Zhubanchaliyev, Maud Kamal, Ivan Bieche, Laure Monard, Clotilde Simon, Delphine Louis, Clint T. Allen, Arun Rajan, James L. Gulley, Maude Guillot-Delost, Christophe Le Tourneau, Hélène Salmon

×

Usage data is cumulative from November 2026 through November 2026.

Usage JCI PMC
Text version 1,335 0
PDF 237 0
Figure 388 0
Supplemental data 132 0
Citation downloads 59 0
Totals 2,151 0
Total Views 2,151

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts